Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-1.22
EPS est.
$-1.18
EPS surprise
-3.83%
1-day move
+2.01%
IDEAYA Biosciences reported a wider loss than expected for the quarter, which typically raises concerns among investors. However, the stock reacted positively, increasing by 2.01%. This could indicate that investors are optimistic about future developments or other factors not captured in the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.22 | $-1.17 | -3.83% |
| Revenue | — | $7M | — |
No transcript is on record, and the analysis is based solely on numerical results.
IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments grows.
Last quarter
In the last quarter, IDEAYA reported an EPS of $-1.11, slightly missing expectations. The stock reacted negatively, dropping 0.35% the following day.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
+8284.17%
Avg 1-day reaction
-2.11%
Analysts are generally expecting a loss of $1.17 per share this quarter, with revenue projected at $7 million. The company has a mixed track record of meeting earnings expectations.
Bull case
If IDEAYA can exceed the EPS estimate and show strong revenue growth, it could signal positive momentum in its drug development pipeline, attracting more investor interest.
Bear case
Conversely, if the company reports a larger loss than expected or fails to generate significant revenue, it may raise concerns about its financial stability and future prospects.
Key metrics to watch
EPS
$-1.17Earnings per share (EPS) is a key indicator of the company's profitability and financial health, especially as it continues to invest in research and development.
Revenue
$7MRevenue figures will provide insight into the company's sales performance and market acceptance of its therapies.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $-1.17?
A better-than-expected EPS could indicate improving operational efficiency and investor confidence in the company's future.
Q2
What is the revenue outlook for the upcoming quarters?
Understanding revenue trends will be crucial for assessing the company's growth trajectory and market acceptance of its products.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate the potential for IDEAYA to achieve better-than-expected results due to its recent advancements in drug development.
Supporting evidence
The company has a history of surprising the market, with a 38% beat rate over the last quarters.
Options pricing suggests a higher volatility expectation, indicating that traders are anticipating significant news.
Recent developments in their pipeline could lead to unexpected revenue streams.
Key risk
If the company reports revenue significantly above $7 million, it could challenge current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to manage costs while advancing its product pipeline.
Bull confirmed if
Reporting an EPS loss of less than $-1.17 and revenue exceeding $7 million would confirm a positive outlook.
Bear confirmed if
An EPS loss greater than $-1.17 and revenue significantly below $7 million would signal ongoing challenges.
What the market is pricing for the move.
Implied Move
±13.3%
Historical Avg
±4.2%
The options market is pricing in a significant move of about 13.3%, indicating that traders expect volatility around the earnings report.
Options are pricing ±13.3% while IDYA has averaged ±4.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
36.9%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If IDEAYA beats expectations, history suggests the stock could rise by about 1.24%, confirming positive momentum.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity.
Miss
A miss could lead to a decline of around 5.05%, reflecting investor disappointment and concerns about the company's future.
The lines on the call that would change the story.